Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.

ABSTRACT: BACKGROUND:Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the half-life of TOP1-DNA cleavage complexes (TOP1cc), ultimately resulting in cell death. In small and non-randomized trials for BC, researchers have observed extensive variation in CPT response rates, ranging from 14 to 64%. This variability may be due to the absence of reliable selective parameters for patient stratification. BC cell lines may serve as feasible models for generation of functional criteria that may be used to predict drug sensitivity for patient stratification and, thus, lead to more appr

SUBMITTER: Tesauro C 

PROVIDER: S-EPMC6884793 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature